Entia Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERGO research report →
Price Chart
About the company
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases.
- CEO
- Timothy A. Timmins
- IPO
- 2008
- Employees
- 6
- HQ
- Sherwood, OR, US
Get TickerSpark's AI analysis on ERGO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.73K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.03
- P/B
- -0.00
- EV/EBITDA
- -0.75
- Div Yield
- 0.00%
- Gross Margin
- 65.53%
- Op Margin
- -439.75%
- Net Margin
- -554.75%
- ROE
- 106.80%
- ROIC
- 126.81%
Latest fiscal year · YoY change
- Revenue
- $265.47K-23.5%
- Gross Profit
- $173.97K-19.4%
- Op Income
- $-1,167,379
- Net Income
- $-1,472,664+38.9%
- EPS
- $-0.05+47.3%
- OCF Growth
- -33.3%
- FCF Growth
- -29.5%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.27
- RSI (14)
- 96
- Avg Volume
- 284
No earnings-call transcripts are available for ERGO yet.
- Free Float
- 58.0%
- Shares Outstanding
- 33.66M
- Float Shares
- 19.53M
of shares held by institutions
1 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 16, 17 | HAUSMAN MARVIN S MD | other | 250,000 |
| Feb 14, 17 | HAUSMAN MARVIN S MD | other | 300,000 |
| Feb 14, 17 | HAUSMAN MARVIN S MD | other | 200,000 |
| Feb 14, 17 | HAUSMAN MARVIN S MD | other | 600,000 |
| Feb 14, 17 | HAUSMAN MARVIN S MD | other | 1,861,170 |
| Feb 14, 17 | Shelton Elliot | other | 250,000 |
| Feb 14, 17 | Shelton Elliot | other | 200,000 |
| Feb 16, 17 | JOHNSON CARL J | other | 250,000 |
| Feb 14, 17 | JOHNSON CARL J | other | 300,000 |
| Feb 14, 17 | JOHNSON CARL J | other | 300,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ERGO coverage
Recent articles, reports, and earnings notes.
No research on ERGO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ERGO report →